Back to Search Start Over

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Authors :
Caitlin A. Contag
Leah Mische
Isabel Fong
Abraar Karan
Akanksha Vaidya
David W. McCormick
William Bower
Jill K. Hacker
Kelly Johnson
Perla SanJuan
Linda Crebbin
Caroline Temmins
Harleen Sahni
Yael Bogler
Joseph D. Cooper
Supriya Narasimhan
Source :
Emerging Infectious Diseases, Vol 29, Iss 12, Pp 2520-2523 (2023)
Publication Year :
2023
Publisher :
Centers for Disease Control and Prevention, 2023.

Abstract

Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.

Details

Language :
English
ISSN :
10806040 and 10806059
Volume :
29
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Emerging Infectious Diseases
Publication Type :
Academic Journal
Accession number :
edsdoj.1338baf33b46a88e0a7a897c9a9ece
Document Type :
article
Full Text :
https://doi.org/10.3201/eid2912.230849